Brain Health & Nootropics
DSIP (Delta Sleep-Inducing Peptide)
← Back to Library
Protocol not independently verified FDA safety flag Circadian Neural
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 5, 10 mg
Dosing window: Pre-Bed
Receptor / target: Delta Sleep Pathways
Properties: Not stated
Pre-mixed: No
Protocol examples
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 100 mcg | Administer 30-60 minutes before bedtime. |
| Week 2 | 150 mcg | Administer 30-60 minutes before bedtime. |
| Week 3 | 200 mcg | Administer 30-60 minutes before bedtime. |
| Weeks 4-8 | 250-300 mcg | Administer 30-60 minutes before bedtime. |
Protocol example from the source dataset; verify against the evidence status and listed sources.
Alternative: Jet Lag / Circadian Reset
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-2 | 200mcg | Used strictly for 1-2 nights following severe time zone changes. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative 2: 12-Week Escalation
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 100mcg 1x Daily | Take dose 30 mins: 1 hour before bedtime. |
| Week 2 | 200mcg 1x Daily | Take dose 30 mins: 1 hour before bedtime. |
| Week 3 | 300mcg 1x Daily | Take dose 30 mins: 1 hour before bedtime. |
| Week 4 | 400mcg 1x Daily | Take dose 30 mins: 1 hour before bedtime. |
| Week 5 | 500mcg 1x Daily | Take dose 30 mins: 1 hour before bedtime. |
| Week 6 | 600mcg 1x Daily | Take dose 30 mins: 1 hour before bedtime. |
| Week 7-12 | 700mcg 1x Daily | Take dose 30 mins: 1 hour before bedtime. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: Nootropic protocols are state-dependent: sleep, anxiety, stimulants, psychiatric history, and route can change the response. The logic is morning-biased, low-entry dosing, and stopping if arousal or mood destabilizes. Entry context: target (Delta Sleep Pathways); route Subcutaneous; timing Pre-Bed. Unapproved or source-dataset dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit.
Independent evidence
Independent safety notes: FDA lists emideltide/DSIP among withdrawn nominated bulk substances with insufficient route-specific safety information.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Narcolepsy: DSIP drives delta sleep-state induction in thalamocortical circuits; in subjects with narcolepsy, which is characterized by dysregulated and abrupt sleep-state transitions (REM intrusions, cataplexy, sleep paralysis), exogenous delta sleep promotion may further destabilize the already-fragile boundary between sleep and wake states.
- Severe major depressive disorder with psychomotor retardation: the altered NREM/REM sleep architecture characteristic of severe depression (shortened REM latency, reduced slow-wave sleep proportion) may respond unpredictably to exogenous DSIP; artificially deepening delta sleep without addressing the underlying HPA axis dysregulation and monoamine depletion could worsen the condition.
- Known hypersensitivity to DSIP or peptide excipients.
- Daytime or non-pre-bed administration: DSIP must be administered within the pre-sleep behavioral window (30-60 minutes before intended sleep onset); administration at any other time of day produces inappropriate drowsiness, circadian disruption, and loss of the specific thalamocortical sleep-induction mechanism.
- Operating heavy machinery, driving, or any safety-critical activity within 4-6 hours of DSIP administration: the delta sleep-inducing effect creates significant drowsiness; subjects must be in a position to sleep following administration.
- Concurrent use with CNS depressants (benzodiazepines, z-drugs, opioids, barbiturates, alcohol): additive CNS depression; the combined sedative effect could produce dangerous respiratory depression and excessive sedation.
- Pregnancy: no safety data; neuromodulatory peptide effects on fetal thalamic and hypothalamic development are not characterized.
- Breastfeeding: no safety data.
- Pediatric use: sleep architecture differs substantially in children and adolescents; safety not established.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Next-day grogginess and lethargy: the most commonly reported adverse effect; dose-dependent; excessive delta sleep induction extends into early morning hours producing post-sleep inertia; most pronounced when doses exceed individual threshold (typically >400mcg); managed by starting at 100mcg and escalating slowly.
- Excessive sedation within the dosing window: if DSIP takes effect before the subject has completed necessary pre-bed activities; the 30-60 minute administration window is a precise recommendation and should be treated as one.
- Unusual dreams or altered dream content: delta sleep promotion alters the REM/NREM cycle architecture; the subsequent REM rebound that follows deep NREM may produce more vivid or intense dreaming in some subjects.
- Morning hypotension and dizziness on standing: sluggish autonomic recovery from deep delta sleep in some subjects; drink water before standing; do not stand abruptly.
- Mild headache on waking: uncommon; possibly related to the altered neurovascular tone during deep sleep or glymphatic activity changes.
- Rebound insomnia on cessation: mild; not a withdrawal syndrome in the pharmacological sense but a functional consequence of DSIP-habituated sleep architecture adjusting back to baseline; typically resolves within 1-3 nights.
- HPA axis modulation: DSIP has documented effects on corticosterone and LH pulsatility; at high doses, chronic use may produce subclinical changes in cortisol awakening response or LH pulse amplitude; monitor in subjects with pre-existing endocrine conditions.
- Tolerance development with continuous long-term use: the mechanistic basis for the 8-12 week cycle limit and 4-8 week washout; continuous exposure reduces the sleep-promoting response as receptor systems adapt.
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.
Sources
- https://the source dataset.com/peptide-codex.php
- https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
- https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks?pg=3
- PubMed search: DSIP (Delta Sleep-Inducing Peptide)